Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 3:9:4.
doi: 10.1186/1748-717X-9-4.

Re-irradiation in the treatment of patients with cerebral metastases of solid tumors: retrospective analysis

Maike Scharp, Henrik Hauswald  1 , Marc Bischof, Juergen Debus, Stephanie E Combs
Affiliations

Re-irradiation in the treatment of patients with cerebral metastases of solid tumors: retrospective analysis

Maike Scharp et al. Radiat Oncol. .

Abstract

Background: Goal of this retrospective analysis was to evaluate the role of repeat whole brain radiotherapy in the palliative care of patients with brain metastases due to solid tumors.

Methods: Data regarding demographic data, primary tumor, metastasis, radiotherapy and symptoms were compiled on 134 patients with cerebral metastases that received repeat whole brain radiotherapy (WBRT) in our clinic between 2002 and 2011.

Results: The analyzed group consisted of 63 (47%) women and 71 (53%) men with a median age of 57 at the start of re-irradiation. Most frequent primary site was the lung (87%).Sixty patients with lung cancer received the first WBRT prophylactically. At the time of re-WBRT 81% of all patients suffered from additional extracerebral metastases.Time between first and second WBRT was a median of 13.4 months. Full dose for the first WBRT was 30 Gy in 2.0 Gy single dose, for the second 20 Gy in 2.0 Gy single dose.At the start of the Re-WBRT 81 patients (60.4%) had mild, 32 (23.9%) severe neurological symptoms, 21 patients (15.7%) were asymptomatic. The median Karnofsky performance status was 70%. Overall, re-WBRT was tolerated satisfactorily. Main side effects were fatigue, erythema and focal alopecia, 10% of patients discontinued treatment before reaching the planned dose. Median survival was 2.8 months since the end of the re-WBRT with good performance status at the start of the re-irradiation being a key indicator for longer survival.Fifty-two patients (39%) showed a clinical improvement of neurological symptoms after the therapy, 59 patients (44%) remained stable, 23 patients (17%) showed worse symptoms.

Conclusions: From this large patient collective we were able to show that re-WBRT can be an important therapeutic option with low rate of acute side effects for patients in adequate general condition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival after re-irradiation (Kaplan-Meier’s estimation).
Figure 2
Figure 2
Overall survival depending on primary tumor site (Kaplan-Meier’s estimation). SCLC with significantly worse prognosis (p = 0.002, log-rank-test).
Figure 3
Figure 3
Overall survival depending on RPA class (Kaplan-Meier’s estimation). RPA class 3 with significantly worse prognosis (p = 0.002, log-rank-test).
See this image and copyright information in PMC

References

    1. Soffietti R, Rudà R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol. 2008;20:676–684. doi: 10.1097/CCO.0b013e32831186fe. - DOI - PubMed
    1. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803. doi: 10.1016/S0360-3016(98)00442-8. - DOI - PubMed
    1. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC, Kalkanis SN. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:17–32. doi: 10.1007/s11060-009-0060-9. - DOI - PMC - PubMed
    1. Hauswald H, Dittmar J-O, Habermehl D, Rieken S, Sterzing F, Debus J, Combs SE. Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiat Oncol. 2012;7:130. doi: 10.1186/1748-717X-7-130. - DOI - PMC - PubMed
    1. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1–9. doi: 10.1016/0360-3016(80)90195-9. - DOI - PubMed

MeSH terms